Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be attending the JonesHealthcare Seaside Summit 2024 being held July 14-16, 2024, in Encinitas, CA.
成就生命科學公司(Nasdaq: ACHV)是一家晚期藥品公司,致力於全球開發和銷售面向戒菸和尼古丁依賴的細膩菸鹼胺。今天宣佈,成就管理人員將參加2024年7月14日至16日在加州恩西尼塔斯舉行的JonesHealthcare Seaside Summit 2024。
John Bencich, CEO of Achieve, will present on Monday, July 15, 2024, at 8:45 AM PDT. Following the presentation, he will also participate in a live panel discussion titled "Introducing Disruptive Products to Established Healthcare Markets—Commercial and Regulatory Considerations" at 10:00 AM PDT. The panel will be hosted by Justin Walsh, PhD, a Healthcare Research Analyst at JonesTrading Institutional Services LLC. To arrange one-on-one meetings and for more information about the conference, please contact your JonesTrading representative directly or visit the Achieve Life Sciences Investor Relations website.
成就的首席執行官約翰·本奇奇(John Bencich)將於2024年7月15日星期一8:45 Am PDt發表演講。在演講後,他還將參加由JonesTrading Institutional Services LLC的醫療保健研究分析師賈斯汀·沃爾什(Justin Walsh)博士主持的名爲“向現有醫療保健市場介紹顛覆性產品的商業和監管考慮因素”空中面板討論,時間爲上午10:00。如欲安排一對一會議或獲取更多關於大會的信息,請直接聯繫JonesTrading代表或訪問成就生命科學公司投資者關係網站。
About Achieve and Cytisinicline
Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3
成就的重點是通過開發和商業化cytisinicline來解決全球吸菸健康和尼古丁成癮的流行病。僅在美國就有大約2800萬成年人吸食可燃香菸。
成就的重點是通過開發和銷售細膩菸鹼胺來應對全球吸菸健康和尼古丁成癮流行病。僅在美國就有約2800萬成年人吸食可燃菸草。1目前,菸草使用是導致全球超過800萬人死亡和近50萬人每年在美國死亡的可防止死亡的主要原因。2,3超過87%的肺癌死亡,61%的所有肺部疾病死亡以及32%的冠心病死亡都歸因於吸菸和接觸二手菸。3
In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping.1 In 2023, approximately 2.1 million middle and high school students in the United States reported using e-cigarettes.4 Currently, there are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation.
此外,美國還有超過1100萬成年人使用電子煙,也稱爲vaping。1在2023年,約210萬中學和高中學生在美國報告使用電子煙。4目前,尚無FDA批准的治療適用於作爲尼古丁電子煙戒斷輔助產品。
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of withdrawal symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve visit .
cytisinicline是一種植物性生物鹼,通過與大腦中的受體相互作用,減輕戒斷症狀的嚴重程度,以及減少與尼古丁製品相關的獎勵和滿足感,有望對治療吸菸和電子煙成癮產生幫助作用。cytisinicline是一種正在開發的潛在產品候選,用於治療尼古丁成癮,未獲得美國FDA批准。了解更多cytisinicline和成就的詳情,請訪問。
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of macroeconomic and geopolitical conditions, including inflation, rising interest rates, increased volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics and geopolitical conflict and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.
前瞻性聲明
本新聞稿包含《1995年私人證券訴訟改革法案》的“安全港”規定下的前瞻性陳述,包括但不限於有關細膩菸鹼胺臨床開發和監管審查和批准的時間和性質、數據結果和商業化活動、細膩菸鹼胺的潛在市場規模、細膩菸鹼胺的潛在益處、功效、安全性和耐受性、發現和開發細膩菸鹼胺的新用途(包括但不限於作爲電子煙戒斷產品),以及新治療的發展和有效性。除了歷史事實陳述外,所有其他陳述都可以被視爲前瞻性陳述。成就可能無法按時實現其計劃或產品開發目標,如果實現,可能未能或無法承擔其在這些前瞻性陳述中披露的意圖或滿足其期望或披露的預期,本新聞稿陳述基於管理層當前的期望和信念,並受到可能導致實際結果與前瞻性陳述中描述的結果有所不同的一些風險、不確定性和假設的影響,此類風險、不確定性和假設包括但不限於細膩菸鹼胺未能表現出假設或預期的益處的風險;成就可能無法獲得用於資助細膩菸鹼胺開發的額外融資的風險;細膩菸鹼胺將不會獲得監管批准或成功商業化的風險;吸菸戒菸領域的新發展需要更改業務戰略或臨床開發計劃的風險;成就的知識產權可能無法得到充分保護的風險;一般商業和經濟條件的風險;與宏觀經濟和地緣政治條件(包括通貨膨脹、利率上升、債務和股票市場的增加波動、實際或感知不穩定的全球銀行體系、全球健康危機和大流行病以及地緣政治衝突)對我們業務的影響有關的風險;以及其他在成就的各種提交的風險因素中所述的因素,包括成就的年度10-k表和季度10-Q表。除了依法所要求的情況外,成就不承擔更新此處所含的前瞻性陳述或體現此處所含的日期之後發生的事項或情況的責任。
Investor Relations Contact
Nicole Jones
achv@cg.capital
(404) 736-3838
投資者關係聯繫人
Nicole Jones
achv@cg.capital
(404) 736-3838
Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
媒體聯繫人
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
References
1Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483.
2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
4Birdsey J, Cornelius M, Jamal A, et al. Tobacco Product Use Among U.S. Middle and High School Students — National Youth Tobacco Survey, 2023. MMWR Morb Mortal Wkly Rep 2023;72:1173–1182.
參考
1Cornelius ME,Loretan CG,Jamal A等。菸草產品使用情況-美國,2021年。MMWR Morb Mortal Wkly Rep 2023年; 72:475-483。
2世界衛生組織。全球菸草流行病報告,2019年。日內瓦:世界衛生組織,2017。
3美國衛生及公衆服務部。吸菸的健康後果-50年進步。外科醫生報告,2014年。
4Birdsey J,Cornelius m,Jamal A等。美國中學和高中學生使用菸草產品-全國青少年菸草調查,2023年。MMWR Morb Mortal Wkly Rep 2023年; 72:1173-1182。